Key result
Omecamtiv mecarbil shortens ventricular APD90 by ~6%, increasing ventricular arrhythmias while suppressing AF.
Why the study?
Omecamtiv mecarbil is a cardiac-selective myosin activator with an incompletely characterized electrophysiological profile.
Does omecamtiv mecarbil alter electrophysiological parameters and arrhythmia susceptibility in a Langendorff-perfused rabbit heart model?
Does omecamtiv mecarbil alter electrophysiological parameters and arrhythmia susceptibility in a Langendorff-perfused rabbit heart model?
Answers are grounded in this paper and cite their sources.
Omecamtiv mecarbil exhibits a substrate-dependent electrophysiological profile, demonstrating ventricular proarrhythmic effects but complex, substrate-dependent pro- and antiarrhythmic effects in the atria.
Omecamtiv mecarbil is a cardiac-selective myosin activator and potential heart failure treatment, but its electrophysiological profile remains incompletely characterized. We investigated omecamtiv mecarbil in a Langendorff-perfused rabbit heart model. Forty-eight rabbit hearts were retrogradely perfused; twenty-four in a ventricular and twenty-four in an atrial setup. In the ventricular setup, action potential duration at 90% repolarization (APD 90 ), QT interval, and dispersion of repolarization were assessed during pacing at seven cycle lengths. After baseline recordings, Group 1 ( n = 12) received 1, 5 and 10 µM omecamtiv mecarbil sequentially, while Group 2 ( n = 12) received 100 µM sotalol followed by 5 µM omecamtiv mecarbil. In the atrial setup, Group 3 ( n = 12) received 5 and 10 µM omecamtiv mecarbil, and Group 4 ( n = 12) received isoproterenol/acetylcholine (IsoACh) to increase atrial fibrillation (AF) susceptibility, followed by 5 µM omecamtiv mecarbil. Omecamtiv mecarbil alone shortened ventricular APD 90 and QT interval, increased dispersion of repolarization, and raised ventricular arrhythmia incidence. Sotalol prolonged APD 90 , QT interval, and dispersion, with a marked rise in VT episodes; additional omecamtiv mecarbil did not further prolong repolarization but increased arrhythmia susceptibility further. In the atrial setup, omecamtiv mecarbil alone prolonged conduction time and increased AF inducibility. Under IsoACh, which shortened atrial APD and refractoriness and increased AF episodes, additional omecamtiv mecarbil slowed atrial conduction and markedly suppressed AF. In summary, omecamtiv mecarbil was proarrhythmic at the ventricular level, particularly under reduced repolarization reserve, but showed antiarrhythmic effects in an IsoACh-induced AF model and proarrhythmic properties in the healthy atrium, indicating a substrate-dependent electrophysiological profile.
No takes yet. Share an insight, caveat, or question.
Wolfes et al. (2026) studied Healthy rabbit hearts (experimental model) (n=48). Omecamtiv mecarbil vs. Baseline was evaluated on Action potential duration at 90% repolarization (APD90) (p=<0.05). Omecamtiv mecarbil shortened ventricular action potential duration and increased arrhythmia incidence, but suppressed atrial fibrillation in an isoproterenol/acetylcholine-induced model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: